ResMed Inc. (NYSE:RMD) reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion. The growth was driven by increased demand for sleep devices and masks portfolio and strong growth across Software as a service business. Gross margin improved 350 bps to 58.5%; non-GAAP gross margin improved 330 bps to 59.1%, mainly due to reduced freight and manufacturing cost improvements, increased average selling prices, and a favorable product mix. Income from operations increased 38%; non-GAAP income from operations up 30%. The company reported adjusted EPS of $2.08, up from ...